First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jose Manuel Perez Garcia, Javier Cortés, Anastasios Stathis, Rogier Mous, Elena López-Miranda, Analía Azaro, Sofia Genta, Paolo Nuciforo, Ana Vivancos, Renata Ferrarotto, Francesco Bertoni, Davide Rossi, Nicole Spardy Burr, Oliver Schönborn-Kellenberger, Karin Jorga, Laura Beni, Rajwinder Lehal, Michael Bauer, Dirk Weber, Elena Garralda
Institutions: Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Istituto Oncologico della Svizzera Italiana, University Medical Center Utrecht, Vall d'Hebron Hospital Universitari, The University of Texas MD Anderson Cancer Center, Institute of Oncology Research, Università della Svizzera italiana, Adenoid Cystic Carcinoma Research Foundation
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2890660749